Ultragenyx Pharmaceutical | RARE - Capital Social Ordinario

Precio De Mercado
19.87
Cambio Diario
-0.55 -2.69%
Mensual
-11.73%
Anual
-49.29%
Q1 Expectativa
19.27




Capital Social Ordinario Cambio Fecha
Acadia Pharmaceuticals USD 169.18M 470K 2025-12
Agios Pharmaceuticals USD 58.45M 169K 2025-12
Alnylam Pharmaceuticals USD 132.38M 585K 2025-12
BioCryst Pharmaceuticals USD 213.06M 2.54M 2025-12
BioMarin Pharmaceutical USD 192.3M 201K 2025-12
Esperion Therapeutics USD 245.22M 39.79M 2025-12
Immunic USD 8K 4K 2024-06
Insmed USD 214.26M 1.67M 2025-12
Ionis Pharmaceuticals USD 161.97M 836K 2025-12
Karyopharm Therapeutics USD 13K 0 2024-09
Kyowa Hakko Kirin JPY 523.49M 2K 2025-12
MacroGenics USD 63.32M 60K 2025-12
Moderna USD 391M 2M 2025-09
Neurocrine Biosciences USD 100.1M 400K 2025-12
PTC Therapeutics USD 81.47M 1.54M 2025-12
Puma Biotechnology USD 5K 0 2024-06
Regeneron Pharmaceuticals USD 105.3M 1.1M 2025-09
Sarepta Therapeutics USD 104.96M 196K 2025-12
Ultragenyx Pharmaceutical USD 96.44M 88K 2025-09
Vertex Pharmaceuticals USD 254M 0 2025-12
Xoma USD 87K 1000 2024-06